Related Experiment Video
Updated: Apr 15, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Genetic and immunologic susceptibility to statin-related myopathy
Jaideep Patel1, H Robert Superko2, Seth S Martin3
1Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Medical College of Virginia-Virginia Commonwealth University Medical Center, Richmond, VA, USA.
Abstract:
Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug toxicity: Idiosyncratic Reactions
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...